Flubromazepam
| Flubromazepam | |
|---|---|
| Flubromazepam_isomer.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Flubromazepam is a benzodiazepine derivative that was first synthesized in 1960. It is known for its anxiolytic, sedative, and hypnotic properties. Flubromazepam is structurally related to other benzodiazepines such as diazepam and flunitrazepam.
Chemical Structure[edit]
Flubromazepam is characterized by the presence of a bromine atom at the 7-position and a fluorine atom at the 2-position of the phenyl ring. The chemical formula is C15H10BrFN2O, and it has a molecular weight of 349.16 g/mol.
Pharmacology[edit]
Flubromazepam acts on the central nervous system by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor. This action results in increased neuronal inhibition, leading to its sedative and anxiolytic effects.
Medical Uses[edit]
While flubromazepam has not been widely used in clinical practice, its pharmacological profile suggests potential use in the treatment of anxiety disorders, insomnia, and seizure disorders. However, due to limited research, its safety and efficacy in humans remain largely unestablished.
Side Effects[edit]
Common side effects of benzodiazepines, including flubromazepam, may include drowsiness, dizziness, confusion, and muscle weakness. Long-term use can lead to tolerance, dependence, and withdrawal symptoms upon cessation.
Legal Status[edit]
The legal status of flubromazepam varies by country. In some jurisdictions, it is classified as a controlled substance due to its potential for abuse and dependence.
